Systems Architecture Case Study: CytoSolve® Enables Scalable Mechanistic Modeling of Interferon Biology for Autoimmune Disease Research at Pfizer

Partner Description

Pfizer
Pfizer is a global biopharmaceutical leader advancing innovative therapies across immunology, inflammation, oncology, and rare diseases. Through its Centers for Therapeutic Innovation (CTI), Pfizer collaborates with advanced technology partners to accelerate translational research and drug discovery.

Challenge

Interferons (IFNs) play a central yet highly complex role in autoimmune diseases such as lupus and dermatomyositis, acting across multiple cell types including hematopoietic stem cells and fibroblasts. Conventional experimental and computational approaches struggle to integrate the vast, heterogeneous IFN literature into a coherent, predictive framework capable of supporting target discovery, biomarker identification, and rational therapeutic development. A scalable architecture was required to model IFN regulatory networks mechanistically while preserving biological detail, experimental provenance, and adaptability across disease contexts.

How CytoSolve® Helped

CytoSolve® partnered with Pfizer’s CTI to deploy its computational systems biology platform as a core mechanistic modeling architecture for interferon biology. The CytoSolve® architecture enabled independent IFN signaling submodels—derived from thousands of peer-reviewed publications—to be integrated without collapsing them into a single monolithic model.

Using this modular, ontology-driven framework, CytoSolve® first established and validated an in silico Interferon Regulatory Network against existing in vitro and in vivo wet-lab data. The architecture was then extended to cell-type–specific implementations, enabling mechanistic simulation of IFN signaling in hematopoietic stem cells and fibroblasts. CytoSolve®’s partitioned model design allowed each biological context to be explored independently while remaining interoperable within a unified systems framework.

Key Benefits Realized

  • Scalable systems architecture for integrating complex IFN signaling pathways
  • Mechanistic validation of in silico predictions against existing wet-lab data
  • Cell-type–specific modeling of interferon effects in hematopoietic stem cells and fibroblasts
  • Reusable computational infrastructure supporting target discovery and biomarker identification
  • Foundation for evaluating single and multi-combination therapeutic strategies in autoimmune disease

Outcome

By October 2016, CytoSolve® had successfully validated the interferon regulatory network models and completed setup and testing of hematopoietic stem cell models, with fibroblast modeling underway and on track for completion. The resulting systems architecture provided Pfizer with a powerful, extensible platform for mechanistic understanding of interferon-driven autoimmune pathology. This collaboration demonstrated how CytoSolve®’s modular systems biology architecture can transform fragmented biological knowledge into a coherent, predictive engine for translational research and therapeutic innovation.